KALV
NASDAQ · Biotechnology
Kalvista Pharmaceuticals Inc
$27.00
+0.01 (+0.04%)
Open$26.98
Previous Close$26.99
Day High$27.00
Day Low$26.98
52W High$27.00
52W Low$9.83
Volume—
Avg Volume2.31M
Market Cap1.44B
P/E Ratio—
EPS$-1.58
SectorBiotechnology
Analyst Ratings
Hold
13 analysts
Price Target
+139.9% upside
Current
$27.00
$27.00
Target
$64.76
$64.76
$35.35
$64.76 avg
$75.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 48.50M | 272.43M | 275.70M |
| Net Income | -108,244,051 | -77,974,346 | -85,417,882 |
| Profit Margin | -223.2% | -28.6% | -31.0% |
| EBITDA | -109,772,064 | -125,574,606 | -125,457,307 |
| Free Cash Flow | — | -59,177,907 | -68,220,346 |
| Rev Growth | — | +3.3% | +15.2% |
| Debt/Equity | 1.11 | 0.07 | 0.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |